secwatch.observer — SEC 8-K summary
======================================

Issuer:     OptimizeRx Corp (OPRX)
CIK:        0001448431
Form:       8-K
Filed at:   2022-08-09T23:59:59+00:00
Accession:  0001213900-22-045885
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

OptimizeRx Q2 revenue up 3% to $14M; GAAP net loss $3.9M, cuts FY2022 guidance
------------------------------------------------------------------------------

- Revenue $14.0M (+3% YoY); gross margin improved to 64% from 59%.
- GAAP net loss $3.9M ($0.21 loss per share) vs net income $0.4M in Q2 2021.
- Non-GAAP net loss $0.7M ($0.04 loss per share) vs $1.8M income year ago.
- Updated FY2022 revenue outlook to $62-68M (1-11% growth), citing temporary industry headwinds.
- Closed EvinceMed acquisition in April; repurchased 232,745 shares under $20M buyback program.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1448431/000121390022045885/0001213900-22-045885-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1448431/000121390022045885/ea164085-8k_optimizerx.htm
  HTML page:      https://secwatch.observer/filing/0001213900-22-045885

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer